Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Notes Payables (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Notes Payables for 6 consecutive years, with $387702.0 as the latest value for Q3 2025.

  • On a quarterly basis, Notes Payables changed 0.14% to $387702.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $387702.0, a 0.14% change, with the full-year FY2024 number at $301660.0, down 64.71% from a year prior.
  • Notes Payables was $387702.0 for Q3 2025 at Ensysce Biosciences, down from $424521.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $12.7 million in Q4 2021 to a low of $245973.0 in Q1 2024.
  • A 5-year average of $2.2 million and a median of $445738.0 in 2023 define the central range for Notes Payables.
  • Peak YoY movement for Notes Payables: surged 1616.54% in 2022, then plummeted 94.43% in 2023.
  • Ensysce Biosciences' Notes Payables stood at $12.7 million in 2021, then crashed by 65.43% to $4.4 million in 2022, then crashed by 80.6% to $854697.0 in 2023, then tumbled by 64.71% to $301660.0 in 2024, then grew by 28.52% to $387702.0 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Notes Payables are $387702.0 (Q3 2025), $424521.0 (Q2 2025), and $257383.0 (Q1 2025).